Company / Revenue per Share
Kymera Therapeutics, Inc. Revenue per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.60
FY2025
5-year range
$0.07 / $1.64
FY2021-FY2025
Trend
-28.6%
vs FY2024
Sector context
#115 of 154
Health Care
What the data says
Kymera Therapeutics, Inc.'s revenue per share of $0.60 is lower than 75% of companies in the Health Care sector (FY2025). Declined from $1.64 to $0.60 over the past 2 years.
Based on SEC 10-K filings.
0.60 in FY2025 with a 5-year CAGR of -16.9%.
Declined from $1.64 to $0.60 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -12.7%
- 5-Year CAGR
- -16.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 154This company $0.60 Sector average $10.35
▼
-94.2% below sector average
Key checks
Key Insights
- In FY2025, revenue per share decreased 28.6% year-over-year.
- Ranks #115 out of 154 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2019.
- Lowest revenue per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.60 | -28.6% |
| FY2024 | $0.85 | -48.3% |
| FY2023 | $1.64 | +80.2% |
| FY2022 | $0.91 | +1277.5% |
| FY2021 | $0.07 | -95.7% |
| FY2020 | $1.52 | -12.0% |
| FY2019 | $1.73 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026